1. Home
  2. ZURA vs PERI Comparison

ZURA vs PERI Comparison

Compare ZURA & PERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$4.37

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

HOLD

Current Price

$8.97

Market Cap

428.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
PERI
Founded
2022
1999
Country
United States
Israel
Employees
40
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
428.3M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
ZURA
PERI
Price
$4.37
$8.97
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$13.00
$14.50
AVG Volume (30 Days)
627.8K
316.8K
Earning Date
05-14-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$9.98
Revenue Next Year
N/A
$2.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$8.07
52 Week High
$7.25
$11.44

Technical Indicators

Market Signals
Indicator
ZURA
PERI
Relative Strength Index (RSI) 38.08 35.07
Support Level $3.33 $8.51
Resistance Level $4.58 $9.62
Average True Range (ATR) 0.36 0.38
MACD -0.03 -0.23
Stochastic Oscillator 26.33 13.64

Price Performance

Historical Comparison
ZURA
PERI

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

Share on Social Networks: